Condition
Graft-versus-Host Disease (GVHD) clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Graft-versus-Host Disease (GVHD) clinical trials that are recruiting, at sites in 2 countries (most in United States (3), China (1)). By phase: Phase 2 (3), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 2Countries
Newest Graft-versus-Host Disease (GVHD) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Allogeneic stem cell transplant with low-dose post-transplant cyclophosphamide to prevent graft-versus-host disease. | Phase 2 | Hershey, Pennsylvania | Recruiting | Apr 13, 2025 |
| Improving GVHD prevention after donor stem cell transplant | Phase 2 | Omaha, Nebraska | Recruiting | Jan 29, 2025 |
| Dapagliflozin to prevent acute graft-versus-host disease after allogeneic stem cell transplant | Phase 2 | Suzhou, Jiangsu | Recruiting | Oct 4, 2024 |
| Comparing two treatment regimens for Graft-versus-host Disease after stem cell transplantation | Phase 3 | Palo Alto, California and 29 other locations | Recruiting | Sep 26, 2024 |
All recruiting trials (4)
-
Allogeneic stem cell transplant with low-dose post-transplant cyclophosphamide to prevent graft-versus-host disease.
This study tests whether giving low-dose (25 mg/kg) cyclophosphamide on days +3 and +4 after allogeneic peripheral blood stem cell transplant can prevent GVHD in adults with blood cancers who receive reduced-intensity or non-myeloablative conditioning.
-
Improving GVHD prevention after donor stem cell transplant
This study will test whether a lower dose versus the standard dose of post-transplant cyclophosphamide, given with sirolimus and MMF, improves quality of life for people aged 60 and older having a reduced-intensity allogeneic stem cell transplant.
-
Dapagliflozin to prevent acute graft-versus-host disease after allogeneic stem cell transplant
This trial will test whether taking dapagliflozin around the time of an allogeneic stem cell transplant can lower the chance of acute graft-versus-host disease in adults with blood cancers.
-
Comparing two treatment regimens for Graft-versus-host Disease after stem cell transplantation
This study is testing two different treatment plans for adults with Graft-versus-host Disease after stem cell transplantation to see which one works better, especially for those who haven't responded to steroids.
Related topics
Quick answers
How many Graft-versus-Host Disease (GVHD) clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (3 trials), China (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.